PE20021032A1 - PHARMACEUTICAL COMPOSITION FOR USE IN THE FAVORABLE MODULATION OF THE QUALITY OF LIFE RELATED TO HEALTH AND TEMPORARY PROGRESSION ADJUSTED TO THE QUALITY RELATED TO THE HEALTH OF A DISEASE IN PATIENTS WITH PROSTATE CANCER - Google Patents

PHARMACEUTICAL COMPOSITION FOR USE IN THE FAVORABLE MODULATION OF THE QUALITY OF LIFE RELATED TO HEALTH AND TEMPORARY PROGRESSION ADJUSTED TO THE QUALITY RELATED TO THE HEALTH OF A DISEASE IN PATIENTS WITH PROSTATE CANCER

Info

Publication number
PE20021032A1
PE20021032A1 PE2002000305A PE2002000305A PE20021032A1 PE 20021032 A1 PE20021032 A1 PE 20021032A1 PE 2002000305 A PE2002000305 A PE 2002000305A PE 2002000305 A PE2002000305 A PE 2002000305A PE 20021032 A1 PE20021032 A1 PE 20021032A1
Authority
PE
Peru
Prior art keywords
health
quality
alkyl
prostate cancer
trans
Prior art date
Application number
PE2002000305A
Other languages
Spanish (es)
Inventor
Talat Ashraf
Amitabh Singh
Robert J Padley
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/832,752 external-priority patent/US20030022811A1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PE20021032A1 publication Critical patent/PE20021032A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE UN ANTAGONISTA DEL RECEPTOR DE ENDOTELINA TAL COMO UN COMPUESTO DE PIRROLIDINA DE FORMULA I-a, DONDE R1 Y R2 SON ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILO, ARILO, HETEROARILO, ALQUILO SUSTITUIDO CON CICLOALQUILO, HALO, ARILO, HETEROARILO, HETEROCICLO, OH, O-ALQUILO; R3 ES R4SO2R5, R4COR5; R4 ES ALQUILO, (CH2)-ALQUENILO, (CH2)ALQUINILO, NR6R7, ENTRE OTROS, R5 ES ENLACE, ALQUILENO, NH-ALQUILENO, N-ALQUIL-ALQUILENO; R6 Y R7 SON H, ALQUILO, (CH2)-ALQUILENO, (CH2)-ALQUINILO, CICLOALQUILO, ARILO, ENTRE OTROS; UTILIZANDO DE 1mg/DIA A 25mg/DIA; EN ASOCIACION CON UN DILUYENTE. SON COMPUESTOS PREFERIDOS ACIDO TRANS,TRANS-2-(4-METOXIFENIL)-4-(1,3-BENZODIOXOL-5-IL)-1-(((N-PROPILAMIN)-CARBONIL)METIL)PIRROLIDIN-3-CARBOXILICO; ACIDO TRANS,TRANS-2-(4-METOXIFENIL)-4-(1,3-BENZODIOXOL-5-IL)-1-(AMINCARBONIL)METIL)PIRROLIDIN-3-CARBOXILICO, (2R,3R,4S)-2-(4-METOXIFENIL)-4-(1,3-BENZODIOXOL-5-IL)-1-(((N,N-DIBUTILAMIN)CARBONIL)METIL)PIRROLIDIN-3-CARBOXILICO, ENTRE OTROS. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DEL CANCER DE PROSTATAREFERS TO A COMPOSITION INCLUDING AN ENDOTHELIN RECEPTOR ANTAGONIST SUCH AS A PYRROLIDINE COMPOUND OF FORMULA Ia, WHERE R1 AND R2 ARE ALKYL, ALKENYL, ALKINYL, CYCLALKYL, ARYL, HETEROYL, SUSTIYL ALKYL, HETEROYL SUSTYL , HETEROCICLO, OH, O-ALKYL; R3 IS R4SO2R5, R4COR5; R4 IS ALKYL, (CH2) -ALKENYL, (CH2) ALKINYL, NR6R7, AMONG OTHERS, R5 IS LINK, ALKYLENE, NH-ALKYLENE, N-ALKYL-ALKYLENE; R6 AND R7 ARE H, ALKYL, (CH2) -ALKYLENE, (CH2) -ALKINYL, CYCLOALKYL, ARYL, AMONG OTHERS; USING FROM 1mg / DAY TO 25mg / DAY; IN ASSOCIATION WITH A THINNER. PREFERRED COMPOUNDS ARE TRANS, TRANS-2- (4-METOXIFENIL) -4- (1,3-BENZODIOXOL-5-IL) -1 - (((N-PROPYLAMIN) -CARBONYL) METHYL) PYRROLIDIN-3-CARBOXYL; TRANS, TRANS-2- (4-METOXYPHENIL) -4- (1,3-BENZODIOXOL-5-IL) -1- (AMINCARBONYL) METHYL) PYRROLIDIN-3-CARBOXYL ACID, (2R, 3R, 4S) -2- (4-METOXYPHENIL) -4- (1,3-BENZODIOXOL-5-IL) -1 - (((N, N-DIBUTYLAMIN) CARBONYL) METHYL) PYRROLIDIN-3-CARBOXYL, AMONG OTHERS. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF PROSTATE CANCER

PE2002000305A 2001-04-11 2002-04-11 PHARMACEUTICAL COMPOSITION FOR USE IN THE FAVORABLE MODULATION OF THE QUALITY OF LIFE RELATED TO HEALTH AND TEMPORARY PROGRESSION ADJUSTED TO THE QUALITY RELATED TO THE HEALTH OF A DISEASE IN PATIENTS WITH PROSTATE CANCER PE20021032A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/832,752 US20030022811A1 (en) 2001-04-11 2001-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US11848602A 2002-04-08 2002-04-08

Publications (1)

Publication Number Publication Date
PE20021032A1 true PE20021032A1 (en) 2002-11-12

Family

ID=26816420

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000305A PE20021032A1 (en) 2001-04-11 2002-04-11 PHARMACEUTICAL COMPOSITION FOR USE IN THE FAVORABLE MODULATION OF THE QUALITY OF LIFE RELATED TO HEALTH AND TEMPORARY PROGRESSION ADJUSTED TO THE QUALITY RELATED TO THE HEALTH OF A DISEASE IN PATIENTS WITH PROSTATE CANCER

Country Status (10)

Country Link
EP (1) EP1379238A1 (en)
JP (1) JP2005503339A (en)
CN (1) CN1514727A (en)
AR (1) AR033465A1 (en)
BR (1) BR0205970A (en)
CA (1) CA2442591A1 (en)
IL (1) IL158071A0 (en)
MX (1) MXPA03009277A (en)
PE (1) PE20021032A1 (en)
WO (1) WO2002085351A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
CA2652345A1 (en) * 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea related applications
CA2904447C (en) 2007-08-22 2017-01-03 Abbvie Deutschland Gmbh & Co Kg Therapy for complications of diabetes
CN117751099A (en) * 2021-08-05 2024-03-22 中国药科大学 Amide compound and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200101234T2 (en) * 1997-08-04 2002-06-21 Abbott Laboratories Endothelin antagonists.

Also Published As

Publication number Publication date
AR033465A1 (en) 2003-12-17
WO2002085351A1 (en) 2002-10-31
MXPA03009277A (en) 2004-03-10
BR0205970A (en) 2003-09-30
IL158071A0 (en) 2004-03-28
CA2442591A1 (en) 2002-10-31
EP1379238A1 (en) 2004-01-14
JP2005503339A (en) 2005-02-03
CN1514727A (en) 2004-07-21

Similar Documents

Publication Publication Date Title
UY27939A1 (en) COMPOUNDS
RU2325389C2 (en) Composition and derivatives of substituted azaindoloxoacetapiperazine characterized by antiviral activity
RU2013111077A (en) DIPEPTID MEDICINE, ITS APPLICATION AND MEDICINE
DE60215919D1 (en) 4-FLUORO-N-INDAN-2-YL BENZAMIDE AND ITS USE AS A MEDICAMENT
PE20070138A1 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ASPARTILE PROTEASES
RU95113862A (en) Pyrrolopyrimidine derivatives, pharmaceutical composition, intermediate compounds
PE20021089A1 (en) TRIAZOLE COMPOUNDS AS CYTOKINE INHIBITORS
PE20060681A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A TACE INHIBITOR IN COMBINATION WITH A SRC KINASE INHIBITOR AND A HER-2 INHIBITOR
CY1118924T1 (en) METHOD FOR THE TREATMENT OF FIRST AUTOPATH
CY1112689T1 (en) COMPOSITION TO IMPROVE KNOWLEDGE AND MEMORY
GB2448255A (en) Compositions and methods relating to treatment of cancer and infectious diseases
PE20021032A1 (en) PHARMACEUTICAL COMPOSITION FOR USE IN THE FAVORABLE MODULATION OF THE QUALITY OF LIFE RELATED TO HEALTH AND TEMPORARY PROGRESSION ADJUSTED TO THE QUALITY RELATED TO THE HEALTH OF A DISEASE IN PATIENTS WITH PROSTATE CANCER
SE0100569D0 (en) New compounds
PE20211733A1 (en) SUBSTITUTE PYRROLIDINE AMIDES
DE122009000036I1 (en) Use of dapoxetine, A selective serotonin uptake inhibitor, for the treatment of sexual dysfunction
SE9802206D0 (en) Novel compounds
ATE364044T1 (en) 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
DE602004015603D1 (en) PYRAZOLOÄ3,4-BÜPYRIDIN-6-ONE AS GSK-3 INHIBITORS
AU8180001A (en) Human growth hormone to stimulate mobilization of pluripotent hematopoietic stemcells
ATE516366T1 (en) REGULATED APTAMER THERAPEUTICS
ATE369348T1 (en) CYCLIZED BENZAMIDE NEUROKININ ANTAGONISTS FOR USE IN THERAPY
EA200400707A1 (en) INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
RU2011138963A (en) METABOLITES, WHICH ARE CERAMID ANALOGUES
PL371746A1 (en) N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
RU2008133287A (en) PHARMACEUTICAL GEL-CONTAINING COMPOSITION FOR LOCAL AND OUTDOOR USE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal